Placenta‑specific protein 8 promotes the proliferation of lung adenocarcinoma PC‑9 cells and their tolerance to an epidermal growth factor receptor tyrosine kinase inhibitor by activating the ERK signaling pathway

Zeng,Xiaofei; Liu,Qing; Yang,Yanhui; Jia,Weikun; Li,Shuping; He,Dongsheng; Ma,Ruidong

doi:10.3892/ol.2019.10911

Placenta‑specific protein 8 promotes the proliferation of lung adenocarcinoma PC‑9 cells and their tolerance to an epidermal growth factor receptor tyrosine kinase inhibitor by activating the ERK signaling pathway

Authors:
- Xiaofei Zeng
- Qing Liu
- Yanhui Yang
- Weikun Jia
- Shuping Li
- Dongsheng He
- Ruidong Ma
View Affiliations

Affiliations: Department of Cardiothoracic Surgery, First Affiliated Hospital of Chengdu Medical College, Chengdu, Sichuan 610500, P.R. China, Department of Cardiothoracic Surgery, Chengdu Fifth People's Hospital, Chengdu, Sichuan 611130, P.R. China, Department of Cardiothoracic Surgery, The First People's Hospital of Neijiang, Sichuan 641000, P.R. China
Published online on: September 24, 2019 https://doi.org/10.3892/ol.2019.10911
Pages: 5621-5627

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Placenta‑specific protein 8 (PLAC8) is a conserved protein with a molecular weight of 12.5 kDa. The specific function of this protein has not been fully elucidated, however, PLAC8 has been found to play an important tumor regulatory role in certain types of cancer, including colon, pancreatic and liver cancer. PLAC8 also participates in the regulation of the cell cycle, autophagy, epithelial‑mesenchymal transition and other cellular functions, indicating its potential as a molecular target worth further investigation. The present study investigated the effect of PLAC8 on the proliferation of lung adenocarcinoma PC‑9 cells and their sensitivity to gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR‑TKI). It was found that the inhibition of PLAC8 expression in PC‑9 cells resulted in significantly decreased proliferation, whereas overexpression of PLAC8 significantly increased the proliferation (P<0.05) of PC‑9 cells. Furthermore, inhibition of PLAC8 expression resulted in decreased activity of the ERK signaling pathway, while PLAC8 overexpression increased activity of this pathway. Inhibition of the ERK signaling pathway with U0126 reversed the effects induced by inhibiting or overexpressing PLAC8 on cell proliferation. In addition, overexpression of PLAC8 significantly decreased the sensitivity of PC‑9 cells to gefitinib, and this effect was reversed by U0126. Overall, these results suggest that PLAC8 is involved in the regulation of proliferation of lung adenocarcinoma PC‑9 cells and impacts their sensitivity to an EGFR‑TKI. Thus, PLAC8 is a potential novel target in lung adenocarcinoma for future studies.

View Figures

View References

1	Cao M and Chen W: Epidemiology of lung cancer in China. Thorac Cancer. 10:3–7. 2019. View Article : Google Scholar : PubMed/NCBI
2	Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China, 2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
3	Imielinski M, Berger AH, Hammerman PS, Hernandez B, Pugh TJ, Hodis E, Cho J, Suh J, Capelletti M, Sivachenko A, et al: Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell. 150:1107–1120. 2012. View Article : Google Scholar : PubMed/NCBI
4	Chen J, Liu X, Xu Y, Zhang K, Huang J, Pan B, Chen D, Cui S, Song H, Wang R, et al: TFAP2C-activated MALAT1 modulates the chemoresistance of docetaxel-resistant lung adenocarcinoma cells. Mol Ther Nucleic Acids. 14:567–582. 2019. View Article : Google Scholar : PubMed/NCBI
5	Dai B, Kong DL, Tian J, Liu TW, Zhou H and Wang ZF: microRNA-1205 promotes cell growth by targeting APC2 in lung adenocarcinoma. Eur Rev Med Pharmacol Sci. 23:1125–1133. 2019.PubMed/NCBI
6	Song J, Wang W, Wang Y, Qin Y, Wang Y, Zhou J, Wang X, Zhang Y and Wang Q: Epithelial-mesenchymal transition markers screened in a cell-based model and validated in lung adenocarcinoma. BMC Cancer. 19:6802019. View Article : Google Scholar : PubMed/NCBI
7	Cong Z, Diao Y, Xu Y, Li X, Jiang Z, Shao C, Ji S, Shen Y, De W and Qiang Y: Long non-coding RNA linc00665 promotes lung adenocarcinoma progression and functions as ceRNA to regulate AKR1B10-ERK signaling by sponging miR-98. Cell Death Dis. 10:842019. View Article : Google Scholar : PubMed/NCBI
8	Liu C, Li H, Jia J, Ruan X, Liu Y and Zhang X: High metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) expression promotes proliferation, migration, and invasion of non-small cell lung cancer via ERK/mitogen-activated protein kinase (MAPK) signaling pathway. Med Sci Monit. 25:5143–5149. 2019. View Article : Google Scholar : PubMed/NCBI
9	Samatar AA and Poulikakos PI: Targeting RAS-ERK signalling in cancer: Promises and challenges. Nat Rev Drug Discov. 13:928–942. 2014. View Article : Google Scholar : PubMed/NCBI
10	Tanimura S and Takeda K: ERK signalling as a regulator of cell motility. J Biochem. 162:145–154. 2017. View Article : Google Scholar : PubMed/NCBI
11	Corcoran RB, Ebi H, Turke AB, Coffee EM, Nishino M, Cogdill AP, Brown RD, Della Pelle P, Dias-Santagata D, Hung KE, et al: EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov. 2:227–235. 2012. View Article : Google Scholar : PubMed/NCBI
12	Wang LF, Li X, Gao YB, Wang SM, Zhao L, Dong J, Yao BW, Xu XP, Chang GM, Zhou HM, et al: Activation of VEGF/Flk-1-ERK pathway induced blood-brain barrier injury after microwave exposure. Mol Neurobiol. 52:478–491. 2015. View Article : Google Scholar : PubMed/NCBI
13	Garces S, Yin CC, Patel KP, Khoury JD, Manning JT Jr, Li S, Xu J, Pina-Oviedo S, Johnson MR, González S, et al: Focal Rosai-Dorfman disease coexisting with lymphoma in the same anatomic site: A localized histiocytic proliferation associated with MAPK/ERK pathway activation. Mod Pathol. 32:16–26. 2019. View Article : Google Scholar : PubMed/NCBI
14	Chen RH, Sarnecki C and Blenis J: Nuclear localization and regulation of erk- and rsk-encoded protein kinases. Mol Cell Biol. 12:915–927. 1992. View Article : Google Scholar : PubMed/NCBI
15	Lenormand P, Sardet C, Pages G, L'Allemain G, Brunet A and Pouyssegur J: Growth factors induce nuclear translocation of MAP kinases (p42mapk and p44mapk) but not of their activator MAP kinase kinase (p45mapkk) in fibroblasts. J Cell Biol. 122:1079–1088. 1993. View Article : Google Scholar : PubMed/NCBI
16	Chang WL, Liu YW, Dang YL, Jiang XX, Xu H, Huang X, Wang YL, Wang H, Zhu C, Xue LQ, et al: PLAC8, a new marker for human interstitial extravillous trophoblast cells, promotes their invasion and migration. 145(pii): dev148932. 2018.
17	Galaviz-Hernandez C, Stagg C, de Ridder G, Tanaka TS, Ko MS, Schlessinger D and Nagaraja R: Plac8 and Plac9, novel placental-enriched genes identified through microarray analysis. Gene. 309:81–89. 2003. View Article : Google Scholar : PubMed/NCBI
18	Kaistha BP, Lorenz H, Schmidt H, Sipos B, Pawlak M, Gierke B, Kreider R, Lankat-Buttgereit B, Sauer M, Fiedler L, et al: PLAC8 localizes to the inner plasma membrane of pancreatic cancer cells and regulates cell growth and disease progression through critical cell-cycle regulatory pathways. Cancer Res. 76:96–107. 2016. View Article : Google Scholar : PubMed/NCBI
19	Li C, Ma H, Wang Y, Cao Z, Graves-Deal R, Powell AE, Starchenko A, Ayers GD, Washington MK, Kamath V, et al: Excess PLAC8 promotes an unconventional ERK2-dependent EMT in colon cancer. J Clin Invest. 124:2172–2187. 2014. View Article : Google Scholar : PubMed/NCBI
20	Wu SF, Huang Y, Hou JK, Yuan TT, Zhou CX, Zhang J and Chen GQ: The downregulation of onzin expression by PKCepsilon-ERK2 signaling and its potential role in AML cell differentiation. Leukemia. 24:544–551. 2010. View Article : Google Scholar : PubMed/NCBI
21	Kinsey C, Balakrishnan V, O'Dell MR, Huang JL, Newman L, Whitney-Miller CL, Hezel AF and Land H: Plac8 links oncogenic mutations to regulation of autophagy and is critical to pancreatic cancer progression. Cell Rep. 7:1143–1155. 2014. View Article : Google Scholar : PubMed/NCBI
22	Mourtada-Maarabouni M, Watson D, Munir M, Farzaneh F and Williams GT: Apoptosis suppression by candidate oncogene PLAC8 is reversed in other cell types. Curr Cancer Drug Targets. 13:80–91. 2013. View Article : Google Scholar : PubMed/NCBI
23	Jin Z, Guan L, Xiang GM and Gao BA: Radiation resistance of the lung adenocarcinoma is related to the AKT-Onzin-POU5F1 axis. Biochem Biophys Res Commun. 499:538–543. 2018. View Article : Google Scholar : PubMed/NCBI
24	Zhang Y, Hu Q, Li G, Li L, Liang S, Zhang Y, Liu J, Fan Z, Li L, Zhou B, et al: ONZIN upregulation by mutant p53 contributes to osteosarcoma metastasis through the CXCL5-MAPK signaling pathway. Cell Physiol Biochem. 48:1099–1111. 2018. View Article : Google Scholar : PubMed/NCBI
25	Segawa S, Kondo Y, Nakai Y, Iizuka A, Kaneko S, Yokosawa M, Furuyama K, Tsuboi H, Goto D, Matsumoto I and Sumida T: Placenta specific 8 suppresses IL-18 production through regulation of autophagy and is associated with adult still disease. J Immunol. 201:3534–3545. 2018. View Article : Google Scholar : PubMed/NCBI
26	Zhao L, Liu S, Xu J, Li W, Duan G, Wang H, Yang H, Yang Z and Zhou R: A new molecular mechanism underlying the EGCG-mediated autophagic modulation of AFP in HepG2 cells. Cell Death Dis. 8:e31602017. View Article : Google Scholar : PubMed/NCBI
27	Gong C, Fang J, Li G, Liu HH and Liu ZS: Effects of microRNA-126 on cell proliferation, apoptosis and tumor angiogenesis via the down-regulating ERK signaling pathway by targeting EGFL7 in hepatocellular carcinoma. Oncotarget. 8:52527–52542. 2017. View Article : Google Scholar : PubMed/NCBI
28	Wang G, Sun J, Liu G, Fu Y and Zhang X: Bradykinin promotes cell proliferation, migration, invasion, and tumor growth of gastric cancer through ERK signaling pathway. J Cell Biochem. 118:4444–4453. 2017. View Article : Google Scholar : PubMed/NCBI
29	Verma N, Muller AK, Kothari C, Panayotopoulou E, Kedan A, Selitrennik M, Mills GB, Nguyen LK, Shin S, Karn T, et al: Targeting of PYK2 Synergizes with EGFR Antagonists in Basal-like TNBC and Circumvents HER3-Associated Resistance via the NEDD4-NDRG1 Axis. Cancer Res. 77:86–99. 2010. View Article : Google Scholar
30	Tanimoto A, Takeuchi S, Arai S, Fukuda K, Yamada T, Roca X, Ong ST and Yano S: Histone deacetylase 3 inhibition overcomes BIM deletion polymorphism-mediated osimertinib resistance in EGFR-mutant lung cancer. Clin Cancer Res. 23:3139–3149. 2017. View Article : Google Scholar : PubMed/NCBI
31	Jia Y, Ying X, Zhou J, Chen Y, Luo X, Xie S, Wang QC, Hu W and Wang L: The novel KLF4/PLAC8 signaling pathway regulates lung cancer growth. Cell Death Dis. 9:6032018. View Article : Google Scholar : PubMed/NCBI
32	Zou ZQ, Zhang LN, Wang F, Bellenger J, Shen YZ and Zhang XH: The novel dual PI3K/mTOR inhibitor GDC-0941 synergizes with the MEK inhibitor U0126 in non-small cell lung cancer cells. Mol Med Rep. 5:503–508. 2012.PubMed/NCBI
33	Ochi N, Takigawa N, Harada D, Yasugi M, Ichihara E, Hotta K, Tabata M, Tanimoto M and Kiura K: Src mediates ERK reactivation in gefitinib resistance in non-small cell lung cancer. Exp Cell Res. 322:168–177. 2014. View Article : Google Scholar : PubMed/NCBI
34	Ito Y, Sasaki Y, Horimoto M, Wada S, Tanaka Y, Kasahara A, Ueki T, Hirano T, Yamamoto H, Fujimoto J, et al: Activation of mitogen-activated protein kinases/extracellular signal-regulated kinases in human hepatocellular carcinoma. Hepatology. 27:951–958. 1998. View Article : Google Scholar : PubMed/NCBI
35	Marks JL, Gong Y, Chitale D, Golas B, McLellan MD, Kasai Y, Ding L, Mardis ER, Wilson RK, Solit D, et al: Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. Cancer Res. 68:5524–5528. 2008. View Article : Google Scholar : PubMed/NCBI
36	Gao X, Chen G, Gao C, Zhang DH, Kuan SF, Stabile LP, Liu G and Hu J: MAP4K4 is a novel MAPK/ERK pathway regulator required for lung adenocarcinoma maintenance. Mol Oncol. 11:628–639. 2017. View Article : Google Scholar : PubMed/NCBI
37	Shigematsu H, Lin L, Takahashi T, Nomura M, Suzuki M, Wistuba II, Fong KM, Lee H, Toyooka S, Shimizu N, et al: Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst. 97:339–346. 2005. View Article : Google Scholar : PubMed/NCBI
38	Shu Y, Wu X, Tong X, Wang X, Chang Z, Mao Y, Chen X, Sun J, Wang Z, Hong Z, et al: Circulating tumor DNA mutation profiling by targeted next generation sequencing provides guidance for personalized treatments in multiple cancer types. Sci Rep. 7:5832017. View Article : Google Scholar : PubMed/NCBI
39	Kato Y, Hosomi Y, Watanabe K, Yomota M, Kawai S, Okuma Y, Kubota K, Seike M, Gemma A and Okamura T: Impact of clinical features on the efficacy of osimertinib therapy in patients with T790M-positive non-small cell lung cancer and acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors. J Thorac Dis. 11:2350–2360. 2019. View Article : Google Scholar : PubMed/NCBI